Adian Valdez on Muck Rack

Adian Valdez

As seen in: Nature, Cell Reports
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Adian

Contact Adian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV

|
By Kaitlin R Sprouse, Marcos Miranda, Nicholas J. Catanzaro, Amin Addetia, Cameron Stewart Verified, Jack Brown, Annie M. Dosey, Adian Valdez, Rashmi Ravichandran, Maggie Ahlrichs, Craig L. Dobbins, Alexis Hand, Catherine Treichel, Alexandra C. Walls, Andrew McGuire, Elizabeth M. Leaf, Ralph S Baric, Alexandra Schafer, David Veesler, Neil King, Cara W. Chao, Miranda L. Hubbard, Grace G. Hendricks, Jackson McGowan, Isabelle Willoughby
| Cell Reports Verified
Keywords MERS-CoV EMPEM nanoparticle vaccine RBD NTD spike Research topic(s) CP: Immunology Introduction The recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the human and economic toll that can accompany the spillover and spread of a zoonotic disease in humans.
Open in Who Shared Issue with article?

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens - npj Vaccines

|
By Marcos Miranda, Chengbo Chen, Kaitlin R Sprouse, Adian Valdez
| Nature Verified
Abstract We previously described a two-component protein nanoparticle vaccine platform that displays 60 copies of the SARS-CoV-2 spike protein RBD (RBD-NP). The vaccine, when adjuvanted with AS03, was shown to elicit robust neutralizing antibody and CD4 T cell responses in Phase I/II clinical trials, met its primary co-endpoints in a Phase III trial, and has been licensed by multiple regulatory authorities under the brand name SKYCovioneTM.
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified